ADC Therapeutics

ADC Therapeutics is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), focused on driving innovation in ADC development with specialized capabilities from clinical to manufacturing and commercialization. Its technology includes an FDA-approved anti-CD19 ADC, and it is seeking expansion of its FDA-approved product ZYNLONTA® (loncastuximab tesirine-lpyl) into earlier lines of diffuse large B-cell and indolent lymphomas, as a single agent and in combinations. The company aims to confront unmet medical needs in patients with hematologic cancers and solid tumors.

ADC Therapeutics is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), focused on driving innovation in ADC development with specialized capabilities from clinical to manufacturing and commercialization. Its proven executional track record includes the first PBD-based ADC receiving accelerated approval from the FDA and conditional approval from the European Commission. The company's technology includes an FDA-approved anti-CD19 ADC, and it is seeking expansion of its FDA-approved product ZYNLONTA® (loncastuximab tesirine-lpyl) into earlier lines of diffuse large B-cell and indolent lymphomas, as a single agent and in combinations. Ameet Mallik joined ADC Therapeutics in May 2022 as Chief Executive Officer.

Commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs).

• ZYNLONTA® (loncastuximab tesirine-lpyl)

  A prescription medicine currently approved to treat adults with certain types of large B-cell lymphoma that has come back (relapsed) or that did not respond to previous treatment (refractory), who have already received two or more treatments for their cancer.

• 2020-08-18

  ADC Therapeutics reports second-quarter 2020 results[5]ADC Therapeutics公布2020年第二季度业绩finanznachrichten.de

  Reported: 2020-08-18

  ADC Therapeutics reported financial results for the second quarter ended June 30, 2020, including a net loss of $126.6 million.

• 2020-05-19

  ADC Therapeutics receives first credit-facility tranche[6]ADC Therapeutics收到信贷额度首笔款项finanznachrichten.de

  Reported: 2020-05-19

  ADC Therapeutics announced receipt of the initial $65.0 million disbursement under its previously announced convertible credit facility with Deerfield and the issuance to Deerfield of $65.0 million in senior secured convertible notes.

• 2020-04-21

  ADC Therapeutics appoints Jennifer Creel as CFO[7]ADC Therapeutics 任命 Jennifer Creel 为首席财务官finanznachrichten.de

  Reported: 2020-04-21

  ADC Therapeutics announced the appointment of Jennifer Creel as its Chief Financial Officer. Creel joins the company from Celgene Corporation.

1. 1ADC Therapeutics | Innovating Science. Inspiring Hope.adctherapeutics.com
2. 2About ADCs | ADC Therapeuticsadctherapeutics.com
3. 3Contact | ADC Therapeuticsadctherapeutics.com
4. 4Leadership | ADC Therapeuticsadctherapeutics.com
5. 5ADC Therapeutics公布2020年第二季度业绩finanznachrichten.de
6. 6ADC Therapeutics收到信贷额度首笔款项finanznachrichten.de
7. 7ADC Therapeutics 任命 Jennifer Creel 为首席财务官finanznachrichten.de
8. 8ADC Therapeutics SA: ADC Therapeutics Reports Fourth Quarter and Year-End 2020 Financial Results and Provides Business Updatesfinanznachrichten.de
9. 9ADC Therapeutics SA: ADC Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Updatesfinanznachrichten.de